PCOS Is Now Polyendocrine Metabolic Ovarian Syndrome (PMOS). Why the Change?

What is PMOS?

Dr. Kumar: PMOS, or polyendocrine metabolic ovarian syndrome, is the new official name for what most people have known as PCOS, or polycystic ovary syndrome. Think of it as a syndrome of hormonal dysregulation, primarily driven by insulin resistance and an excess of male hormones like testosterone. The disorder happens to involve the ovary, but it is far from limited to it.

Why the name change?

Dr. Kumar: The reason for the change is scientific accuracy: The term PCOS obscured the wide-ranging endocrine and metabolic features of the condition, which caused delayed diagnoses, fragmented care, and stigma, while curtailing research. 

We have known for a long time that calling it "polycystic ovary syndrome" was a misnomer. You do not need to have cysts to have PMOS. The name change should help with this, but it will take time for the culture to catch up.  

The name change also creates research momentum. Future research may further refine PMOS subtypes and enable more personalized treatment.

Who chose the new name and how?

Dr. Kumar: This was not a rebranding. It was a rigorous, decade-long scientific process involving about 22,000 experts across the globe: Doctors, researchers, patients and advocacy groups all contributed. The consensus was published in The Lancet on May 12, 2026, and endorsed by over 56 major academic, clinical and patient organizations. 

Who is affected by PMOS?

Dr. Kumar: PMOS affects one in eight women. That's more than 170 million people worldwide. It typically manifests during the reproductive years, often becoming apparent in early adulthood or puberty, which adds complexity because some features of normal puberty can overlap with PMOS signs and symptoms.

But the condition is frequently not diagnosed until a woman is actively trying to conceive and encounters difficulty. That diagnostic delay is one of the central problems the name change is meant to address. 

What are the signs and symptoms of PMOS?

Dr. Kumar: PMOS can look different in different women, which is part of why it's so underdiagnosed and misunderstood. We look for three signs:

1. Evidence of excess androgen (male hormone), which can cause hair growth on the face (called hirsutism), acne, or androgenic alopecia (also known as male pattern baldness).
2. Irregular or absent periods, which can be a sign of infrequent or absent ovulation. 
3. Ovarian cysts that can be visible on an ultrasound. 

Patients who experience two or more of these typically meet the criteria for a PMOS diagnosis. 

But what the name change emphasizes is what often isn't captured in that triad: insulin resistance, which is present in the majority of patients. The side effects of insulin resistance include: 

• Weight gain or difficulty with weight management. 
• Cardiometabolic risk factors, including abnormal lipid levels in the blood and elevated blood pressure.  
• Fluctuations in hormones with impacts on weight, metabolic and mental health, skin, and the reproductive system.  
• Anxiety and depression. 

Why is it sometimes difficult for patients to get a PMOS diagnosis? Will the name change affect how this condition is diagnosed? 

Dr. Kumar: There are several layers to this. First, many women were told “your ultrasound is normal, you don't have PCOS,” when in fact ovarian health is just one component of a diagnosis, and not even the most important one.  

Second, the condition looks different in different women. A lean woman with irregular periods and no obvious excess hair growth doesn't fit the stereotype, so she might get missed. 

Third, when the condition is framed as a gynecological problem, it tends to be managed by gynecologists alone, and the metabolic workup evaluating insulin resistance, lipids, and glucose tolerance gets deprioritized. 

Will the new name affect treatment? 

Dr. Kumar: I hope so. Right now, treatment for PMOS is often narrowly oriented around the most obvious symptoms. For example, if a patient wants to get pregnant, her treatment addresses that. If she comes in with acne, she gets a birth control pill.  

In my practice, I approach PMOS as a metabolic condition first. That means lifestyle medicine, nutritional strategies, and, when appropriate, medication to control blood sugar levels and increasingly GLP-1 receptor agonists, which have shown real promise in improving both the metabolic picture and optimizing fertility.  

Can PMOS be cured? 

Dr. Kumar: Not completely, but it can be managed. This is a lifelong condition with genetic predisposition. But I want patients to understand that “lifelong” does not mean “untreatable.” Symptoms can be significantly improved, metabolic risk can be mitigated, and fertility outcomes are often achievable with the right interventions.  

What should a person do if she suspects she might have PMOS? 

Dr. Kumar: Advocate for yourself. Specifically, ask your clinician about a workup for PMOS. Don't let “your ultrasound looks fine” be the end of the conversation. A proper evaluation includes a detailed menstrual history, assessment for clinical signs of androgen excess, serum androgens, fasting insulin and glucose, a lipid panel, and an ultrasound in combination with your whole health picture.  

I would encourage women to seek out an endocrinologist, an internist with metabolic medicine expertise, or a reproductive endocrinologist who thinks beyond fertility alone. And if you don't feel heard, find someone else. This condition has a long history of being dismissed, and women deserve rigorous, comprehensive care.